A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced Hepatocellular Carcinoma

Trial Profile

A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Erdafitinib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 16 Jun 2017 Planned primary completion date changed from 20 Aug 2017 to 31 May 2019.
    • 20 Jan 2017 Planned End Date changed from 1 Jun 2019 to 1 May 2019.
    • 25 Nov 2016 Planned number of patients changed from 52 to 58.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top